FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
Posted:
The Food and Drug Administration expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
At this year’s GIANT Health event, we were delighted to welcome Dr. Tom Coffey, OBE as part of the panel “A Brighter Future for Joined-Up London.”
The discussion explored how collaboration, innovation, and system-wide thinking can shape a more connected…
This year’s GIANT Health event created plenty of excitement. As the noise fades, meaningful lessons remain—many pointing toward a future filled with advanced technology and robotic surgery. Yet the clearest picture isn’t found in bold predictions, but in the small,…
Attendees
Sponsors and Exhibitors
Contact us